 |
Longer-Lasting HIV Meds Are on the Horizon
POZ | December 26, 2023
|
|
Preexposure Prophylaxis to Prevent Acquisition of HIV
American Family Physician | December 2023
|
|
Expert: The Evolution of HIV Care, Treatment Options, How Pharmacists Can Assist in Providing Care
Pharmacy Times | December 18, 2023
|
|
Why taking your HIV treatment properly is important
aidsmap | December 2023
|
|
Hospitals are abusing this drug discount program
Washington Blade | December 8, 2023
|
|
AIDS. 2023 Dec 1;37(15):2271-2286. doi: 10.1097/QAD.0000000000003704. Epub 2023 Nov 16.
|
|
NIH Statement on Preliminary Efficacy Results of First-in-Class Gonorrhea Antibiotic
HIV.gov | November 14, 2023
|
|
Risk Factors for Dolutegravir Resistance Identified in Patients With HIV
Infectious Disease Advisor | November 14, 2023
|
|
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis
The Lancet | November 2023
|
|
Quality of Life of People Living with HIV on Antiretroviral Therapy
Dove Medical Press | November 10, 2023
|
|
Commercial Determinants of Access to HIV Preexposure Prophylaxis
JAMA | November 10, 2023
|
|
Rukobia Still Effective at Five Years for People With Drug-Resistant HIV
POZ Magazine | November 8, 2023
|
|
Implementation of Long-Acting Drugs for Treatment and Prevention of HIV
IAS-USA | November 2023
|
|
Trial Shows Limited Resistance to Sunlenca in Patients with HIV
Managed Healthcare Executive | October 23, 2023
|
|
2 Year Data on Lenacapavir Reinforces Clinical Profile for Adults With Multi-Drug Resistant HIV
Contagion Live | October 21, 2023
|
|
Single High-Dose Liposomal Amphotericin B Safe for HIV-Associated Fungal Infections
Infectious Disease Advisor | October 19, 2023
|
|
IDWeek 2023: New Data Provide Closer Look at Real-World Utilization of Cabotegravir for HIV PrEP
Patient Care Online | October 15, 2023
|
|
Pre-Exposure Prophylaxis
HIV.gov | September 28, 2023
|
|
Another class of cancer drugs may contribute to curing HIV
Aidsmap | September 18, 2023
|
|
Observations from ID and Beyond: Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy — Time to Change Treatment Guidelines?
NEJM | September 25, 2023
|
|
Infectious Disease Advisor | September 22, 2023
|
|
Can a Shot to Prevent HIV Make a Dent in America’s Epidemic?
US News | September 21, 2023
|
|
Doxycycline Improves Outcomes of Early Syphilis in Patients With HIV
Infectious Disease Advisor | September 20, 2023
|
|
Two-drug antiretroviral regimens for HIV
The BMJ | September 1, 2023
|
|
Lenacapavir: Drug Offers New Hope for Multi-drug Resistant HIV
Yale School of Medicine - Yale University | August 30, 2023
|
|
HIV Virologic Suppression Maintained After Switch to Long-Acting ART
Infectious Disease Advisor | August 30, 2023
|
|
Overcoming HIV Drug-Resistance Mechanisms
Infectious Disease Special Edition | August 18, 2023
|
| |
|
|
|
MSF refuses to sign ViiV's last-minute NDA for access to most-effective HIV prevention drug CAB-LA
MSF Access Campaign | August 17, 2023
|
|
PrEP use and HIV incidence among youth at-risk for HIV infection in Los Angeles and New Orleans: Findings from ATN 149
J Acquir Immune Defic Syndr. 2023 Aug 14. doi: 10.1097/QAI.0000000000003272.
|
|
Switch to Dolutegravir/Lamivudine Works Well Despite Resistance Mutations
POZ Magazine | August 11, 2023
|
|
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and...
NIH | August 8, 2023
|
|
Immune-modulating medication may help clear HIV reservoir
Aidsmap | August 5, 2023
|
|
More Time on Dolutegravir Needed Before Drug Switch: Study
Medscape | August 4, 2023
|
|
Not 'if' but 'when': Antibiotic resistance poses existential threat for modern medicine
usatoday.com | July 30, 2023
|
|
Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis
NIH | July 27, 2023
|
|
How Gilead Profited by Slow-Walking a Promising H.I.V. Therapy
The New York Times | July 22, 2023
|
|
Walmart Opens 70 More HIV-Focused Pharmacies
POZ Magazine | July 7, 2023
|
|
Drug Pricing Advisory Boards: What They Are and Why They Matter to Patients
HIV/HCV Watch | July 2023
|
|
Long-Acting, Injected HIV Meds Can Help Tough-to-Treat Patients
USNews.com | July 5, 2023
|
|
USFDA gives tentative approval to Lupin's HIV/AIDS drug
The Financial Express | July 4, 2023
|
|
2023 Treatment Guide: Dealing With HIV Med Side Effects?
HIVPlusMag.com | July 3, 2023
|
|
Gilead prevails in $3.6 billion antitrust trial over HIV meds
Courthouse News Service | June 30, 2023
|
|
Updates to HIV Clinical Guidelines on Prevention and Treatment of Opportunistic Infections
HIV.gov | June 28, 2023
|
|
The HIV-1 capsid core is an opportunistic nuclear import receptor
Nature Communications | June 24, 2023
|
|
Second-Line Switch to Dolutegravir for Treatment of HIV Infection
New England Journal of Medicine | June 2023
|
|
What happens to HIV drugs in the body, and do missed doses matter?
Aidsmap | June 2023
|
|
Real-world data confirm the efficacy of dolutegravir-based dual therapy
Aidsmap | May 29, 2023
|
|
Interest Grows in Long-Acting Injectables for HIV Treatment
Pharmacy Times | March 17, 2023
|
|
Implementing Long-acting Injectable PrEP with an Eye Toward Equity: Yale's Dr. LaRon ...
HIV.gov | March 2, 2023
|
|
New HIV Treatment and PrEP Guidelines
POZ Magazine | February 13, 2023
|
|
Sunlenca Looks Great for Highly Drug-Resistant HIV. Will It Serve a Broader Purpose?
TheBody | January 31, 2023
|
|
Baseline Resistance to Second-Generation INSTIs, First-Line NRTIs Unlikely in HIV
Infectious Disease Advisor | January 30, 2023
|
|
A Treatment Timeline
POZ Magazine | January 17, 2023
|
|
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
Lancet HIV. 2023 Jan;10(1):e15-e23. doi: 10.1016/S2352-3018(22)00291-0.
|
| |
|
|
